Finerenone and Left Ventricular Hypertrophy in Chronic Kidney Disease and Type 2 Diabetes
In conclusion, the overall CV and kidney benefits of finerenone versus placebo were not modified by the presence of LVH at baseline, with overall safety findings being similar between LVH subgroups. A greater benefit was observed for HHF in patients with versus without LVH, suggesting that LVH may be a predictor of the treatment effect of finerenone on HHF.
Authors
- Stefan D. Anker (ORCID: https://orcid.org/0000-0002-0805-8683)
- George L. Bakris (ORCID: https://orcid.org/0000-0003-1183-1267)
- Alfredo E. Farjat (ORCID: https://orcid.org/0000-0001-6105-350X)
- Piotr Ponikowski (ORCID: https://orcid.org/0000-0002-3391-7064)
- Gerasimos S Filippatos (ORCID: https://orcid.org/0000-0002-5640-0332)
- Luís M. Ruilope (ORCID: https://orcid.org/0000-0001-6278-7951)
- Stephan von Haehling (ORCID: https://orcid.org/0000-0002-9818-042X)
- Bertram Pitt (ORCID: https://orcid.org/0000-0001-5880-275X)
- Andrew J.S. Coats (ORCID: https://orcid.org/0000-0002-2771-4260)
- Meike Brinker (ORCID: https://orcid.org/0000-0002-1560-9535)
- Giuseppe Rosano (ORCID: https://orcid.org/0000-0002-6868-4248)
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
- Luke Roberts
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Bayer (United States) (US)
- Università degli studi di Cassino e del Lazio Meridionale (IT)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- The Heart Research Institute (AU)
- Wroclaw Medical University (PL)
- University of Chicago (US)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Hospital Universitario 12 De Octubre (ES)
- EP Analytics (United States) (US)
- Universitätsmedizin Göttingen (DE)
- German Centre for Cardiovascular Research (DE)
- Bayer (United Kingdom) (GB)
- Bayer (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1002/ehf2.14962
- Citations
- 10
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 4.02
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Bayer
- Sanofi
- Gilead Sciences
- Alnylam Pharmaceuticals
- Edwards Lifesciences
- Helsinn
- Deutsches Zentrum für Herz-Kreislaufforschung
- Steno Diabetes Center Copenhagen
- Impulse Dynamics
- European Commission
- Novo Nordisk
- Astellas Pharma
- Vifor Pharma
- Servier
- Chugai Pharmaceutical
- Abbott Vascular
- Bayer, United Kingdom
- University of Chicago Medicine
- Respicardia
- Relypsa